The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy

Perspectives in Medicinal Chemistry

Volumn 2008, Issue 2, 2008, Pages 57-73

  Lu, Xinjie ^a   Lu, Dong ^b   Scully, Mike ^a   Kakkar, Vijay ^a  

^a THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Cancer; Disintegrin; Integrin; Ligand

Indexed keywords

ANGIOCIDIN; ANGIOGENESIS INHIBITOR; BCH 14661; BCH 15046; BETA1 INTEGRIN; CD51 ANTIGEN; CILENGITIDE; CNTO 95; DISINTEGRIN; E 7820; EMD 66203; EOS 200 4; INTEGRIN; MEDI 552; MONOCLONAL ANTIBODY LM 609; NATALIZUMAB; S 247; S 36578 2; SC 68448; SCH 221153; SJ 749; ST 1646; UNCLASSIFIED DRUG; VOLOCIXIMAB;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; METASTASIS; MONOTHERAPY; MULTIPLE SCLEROSIS; NONHUMAN; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN STRUCTURE; REVIEW; SOLID TUMOR; TUMOR VASCULARIZATION;

EID: 77649342167     PISSN: None     EISSN: 1177391X     Source Type: Journal    
DOI: 10.1177/1177391x0800200003     Document Type: Review

References (224)

1. Ahmed, N., Riley, C., Rice, G.E. et al. 2002. Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer. J. Histochem. Cytochem., 50:1371-80.
2. Ahmed, N., Riley, C., Rice, G. et al. 2005. Role of integrin receptors for fibronectin, collagen anti laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp. Metastasis, 22:391-402.
3. Agrez, M., Gu, X., Turton, J. et al. 1999. The alpha v beta 6 integrin induces gelatinase B. secretion in colon cancer cells. Int. J. Cancer, 81:90-7.
4. Alghisi, G.C. and Ruegg, C. 2006. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium, 13:113-35.
5. Anderson, J.A., Grabowska, A.M. and Watson, S.A. 2007. PTHrP increases transcriptional activity of the integrin subunit alpha(5). Br J. Cancer, [Epub ahead of print].
6. Arihiro, K., Kaneko, M., Fujii, S. et al. 2000. Significance of alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma. Breast Cancer, 7:19-26.
7. Aumailley, M., Gurrath, M., Muller, G. et al. 1991. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett, 291:50-4.
8. Bartsch, R., Wenzel, C., Zielinski, C.C. e al. 2007. HER-2-Positive Breast Cancer: Hope Beyond Trastuzumab. Bio. Drugs, 21:69-77.
9. Baselga, J., Tripathy, D., Mendelsohn, J. et al. 1996. Phase II study of weekly intravenous recombinant humanized inti-p185HER.2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol, 14:737-44.
10. Bayless, K.J., Salazar, R. and Davis, G.E. 2000. RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. Am. J. Pathol, 156:167-83.
11. Beer, A.J., Haubner, R., Sarbia, M. et al. 2000. Positron emission tomography using [18F]Gatacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer. Res., 12:3942-9.
12. Belvisi, L., Riccioni, T., Marcellini, M. et al. 2005. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist. Mol. Cancer. Ther., 4:1670-80.
13. Belvisi, L., Bernardi, A., Colombo, M. et al. 2006. Targeting integrirs: insights into structure and activity of cyclio RGD pentapeptide mimics containing azabicycloalkane amino acid. Bioorg. Med. Chem., 14:169-80.
14. Berman, A.E. and Kozlova, N.I. 2000. Integrins: structure and functions. Membr Cell. Biol., 13:107-44.
15. Binnerts, M.E., van Kpoyk, Y., Edwards, C. et al. 1996. Antibodies that selectively inhibit leukocyte function -associated antigen 1 binding to intercellular adhesion molecule-3 recognize a unique epitope within the CD11a I domain. J. Biol. Chem., 271:9962-8.
16. Bon, G., Folgiero, V., Di Carlo, S. et al. 2001. Involvement of alpha6beta4 integrin in the mechanisms that regulate breast cancer progression. Breast Cancer Res., 9:203.
17. Bonaccorsi, L., Carloni, V., Muratori, M. et al. 2000. Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype. Endocrinology, 141:3172-82.
18. Brakebusch, C., Wennerberg, K., Krell, H.W. et al. 1999. β1 integrin promotes but is not essential for metastasis of ras-myc transformed fibroblasts. Oncogene, 18:3852-61.
19. Brooks, P.C., Clark, R.A. and Cheresh, D.A. 1994. "Requirement of vascular integrin alpha v beta 3 for angiogenesis" 264:569-71.
20. Brower, D.L., Brower, S.M. and Hayward, D. C. 1997. Molecular evolution of integrins: genes encoding integrin beta subunits from a coral and a sponge. Proc. Natl. Acad. Sci., U.S.A. 94:9182-87.
21. Buckley, C.D., Pilling, D., Henriquez, N.V. et al. 1999. RGD peptides induce apoptosis by direct caspase-3 activation. Nature, 397:534-9.
22. Burgeson, R.E. and Christiano, A.M. 1997. The dermal-epidermal junction. Curr Opin.. Cell. Biol., 9:65 1-8.
23. Byzova, T.V., Goldman, C.K. and Pampori N. 2000. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol. Cell., 6:851-60.
24. Cardones, A.R. and Banez, L.L. 2004. VEGF inhibitors in cancer therapy. Curr. Pharm. Des., 12:387-94.
25. Cao, Q., Cai, W, Li, T. et al. 2006. Combination of integrin siRNA and irradiation for breast cancer therapy. Biochem. Biophys. Res. Commun., 351:726-32.
26. Carron,. C.P., Meyer, D.M., Engleman, V.W. et al. 2000. Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, ndt osteoclast adhesion to bone. J. Endocrinol., 165:587-98.
27. Carpenter, A.E. and Sabatini, D.M. 2004. Systematic genome-wide screens of gene function. Nature Rev. Genet., 5: 11-22.
28. Chan, B.M., Kassner, P.D., Schiro, J.A. et al. 1992. Distinct cellular functions mediated by different VLA integrin alpha subunit cytoplasmic domains. Cell., 68:1051-60.
29. Chow, T.W., Hellums, J.D., Moake, J.L. et al. 1992. Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. Blood, 80:113-20.
30. Cresswell, J., Wong, W.K., Henry, M.J. et al. 2002. Adhesion of lymphocytes to bladder cancer cells: the role of the alpha(E)beta(7) integrin. Cancer Immunol, Immunother., 51:483-91.
31. Chung, K.H., Kim, S.H., Han, K-Y. et al. 2003. Inhibitory effect of salmosin, a Korean snake venom-derived disintegrin, on the integrin alphaV-mediated proliferation of SK-Mel-2 human melanoma cells. J. Pharm. Pharmacol., 55:1577-82.
32. Chung, J. and Mercurio, A.M. 2004. Contributions of the alpha6 integrins to breast carcinoma survival and progression. Mol. Cells, 17:203-9.
33. Coller, B.S. 200 1. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb. Haemost, 86:427-43.
34. Colombatti, A., Bonaldo, P. and Doliana, R. 1993. Type A modules: interacting domains found in several non-fibrillar collagens and in other extracellular matrix proteins. Matrix, 13:297-306.
35. Conway, E.E. Jr. 1993. Central nervous system findings and intussuception: how are they related? Pediatr. Emerg. Care., 9:15-8.
36. Cruz-Monserrate, Z., Qiu, S., Evers, B.M. et al, 2001. Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression. Mod. Pathol., 20:656-67.
37. Dangerfield, J., Larbi, K.Y., Huang, M.T. et al. 2002. PECAM-1 (CD31) homophilic interaction up-regulates alpha6beta1 on transmigrated neutrophils in vivo and plays a functional role in the ability of alpha6 integrins to mediate leukocyte migration through the perivascular, basement membrane. J. Exp. Med., 196:120 1-11.
38. Davidson, B.L. and Paulson, H.L. 2004. Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol., 3:145-9.
39. Davis, G.E. 1992. Affinity of integrins for damaged extracellular matrix: alpha v beta 3 binds to denatured collagen type I through RGD sites. Biochem. Biophys. Res. Commun., 182:1025-31.
40. Davis, T.L., Cress, A.E., Dalkin, B.L. et al. 2001. Unique expression pattern of the alpha6beta4 integrin and laminin-5 in human prostate carcinoma. Prostate, 46:240-8.
41. de Fougerolles, A.R. and Springer, T.A. 1992. Intercellular adhesion molecule 3, a third adhesion counter-receptor for lymphocyte function-associated molecule 1 on resting lymphocytes. J. Exp. Med., 175:185-90.
42. Dechantsreiter, M.A., Planker, E., Matha, B. et al. 1999. N-methylated cyclic RGD peptides as highly active and selective a(V)h(3) integrin antagonists. J. Med. Chem., 42:3033-40.
43. Della Morte, R., Squillacioti, C., Garbi, C. et al. 2000. Echistatin inhibits ppl25FAK autophosphorylation, paxillin phosphorylation and ppl25FAK-paxillin intraction in fibronectin-adherent melanoma cells. Eur. J. Biochem., 267:5047-54.
44. Demetriou, M.C., Pennington, M.E., Nagle, R.B. et al. 2004. Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer. Exp. Cell. Res., 294:550-8.
45. Dittmer, A., Vetter, M., Schunke, D. et al. 2006. Parathyroid hormone-related protein regulates tumor-relevant genes in breast cancer cells. J. biol. Chem., 281:14563-72.
46. Duque, H., LaRocco, M., Golde, W.T. et al. 2004, Interactions of foot-and-mouth disease virus with soluble bovine alpha v beta 3 and alphav beta 6 integrins. J. Virol., 78:9773-81.
47. Elbashir, S.M., Harborth, J. and Weber, K. 2002. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods, 26:199-213.
48. Eliceiri, B.P., Klomke, R., Stromblad, S. et al. 1998. Integrin alphaVbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. Journal of Cellular Biology, 140:1255-63.
49. Eliceiri, B.P. 2001. Integrin and growth factor receptor crosstalk. Circ. Res., 89:1104-10.
50. Enserink, J.M., Methi, T., Mahic, M. et al. 2004. The cAMP-Epac-Rap1 pathway regulates cell spreading and cell adhesion to laminin-5 through the alpha3beta1 integrin but not the alpha6beta4 integrin. J. Biol. Chem., 279:44889-96.
51. Erdreich-Epstein, A., Shimada, H., Groshen, S. et al. 2000. Integrins alpha(v)beta3 and alpha(v)beta5 are expre~sed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res., 60:712-21.
52. Falcioni, R., Antonini, A., Nistico, R et al. 1997. Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 human carcinoma cell lines. Exp. Cell. Res., 236:76-85.
53. Felding-Habermann, B., Fransvea, E., O'Toole, T.E. et al. 2002. Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin. Exp. Metastasis, 19:427-36.
54. Ferrer, F.A., Miller, L.J., Andrawis, R.I. et al. 1998. Angiogenesis and prostate cancer: in vivo and in vitro of expression of angiogenesis factors by prostate cancer cells. Urology, 51:101-7.
55. Ferrer, F.A., Miller, L.J., Lindquist, R. et al. 1999. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology, 54:567-72.
56. Folgiero, V., Bachalder, R.E., Bon, G. et al. 2007. The alpha6beta4 integrin can regulate ErbB-3 expression: implication~ for alpha6beta4 signaling and function. Cancer Res., 67:1645-52.
57. Francis, S.E., Goh, K.L., Hodivala-Dilke, K. et al. 2002. Central roles of alpba5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arteriosclerosis Thrombosis and Vascular Biology, 22:927-33.
58. Frieser, M., Hallmann, R., Johansson, S. et al. 1906. Mouse polymorphonuclear granalocyte binding to extracellular matrix molecules involves beta 1 integrins. Eur J. Immunol., 26:3127-36.
59. Fu, W.M., Chang, T.K., Sun, W.Z. et al. 2004. Inhibition of neuropathic pain by a potent disintegrin - triflavin. Neurosci Lett., 368:263-8.
60. Fujiwara, H., Kikkawa, Y., Sanzen, N. et al. 2001. Purification and characterization of human laminin-8. Laminin-8 stimulates cell adhesion and migration through alpha3beta1 and alphabeta1 integrins. J. Biol. Chem., 276: 17550-8.
61. Galliher, AJ. and Schiemann, W.P. 2006. Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res., 8:R.42.
62. Ganju, P. and Hall, J. 2004. Potential applications siRNA for pain therapy. Expert Opin. Biol. Ther., 4:531-42.
63. Gardner, J.M. and Hynes, R.O. 1985. Interaction of fibronectin with its receptor on platelets. Cell., 42:439-48.
64. Gettrier, S.N., Kenyon, C. and Reichardt L.F. 1995. Characterization of beta pat-3 heterodimers, a family of essential integrin receptors in C. elegans. J. Cell. Biol., 129:1127-41.
65. Giancotti, F.G. and Ruoslahti, E. 1999. Integrin signaling. Science, 285:1028-32.
66. Giannelli, G., Sgarra, C., Di Naro, E. et al. 2007. Endometriosis is characterized by an impaired localization of laminin-5 and alpha3beta1 integrin receptor. Int. J. Gynecol. Cancer, 17:242-7.
67. Gladson, C.L., Hancock, S., Arnold M.M. et al. 1996. Stage-specific expression of integrin alphaVbeta3 in neuroblastic tumors. Am. J. Pathol., 148:1423-34.
68. Golubkov, V., Hawes, D. and Markland, F.S. 2003. Anti-angiogenic activity of contortrostatin, a disintegrin from Agkistrodon contortrix contor-trix snake venom. Angiogenesis, 6:213-24.
69. Gould, R.J., Polokoff, M.A., Friedman, PA. et al. 1990. Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proc. Soc. Exp. Biol. Med., 195:168-71.
70. Gramoun, A., Shorey, S., Bashutski, J.D. et al. 2007. Effects of Vitaxin(R), a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro. J. Cell. Biochem., 102:341-52.
71. Green, P.M., Ludbrook, S.B., Miller, D.D. et al. 2001. Structural elements of the osteopontin SVVYGLR. motif important for the interaction with alpha(4) integrins. FEBS Lett., 503:75-9.
72. Grzesiak, J.J. and Bouvet, M. 2007. Determinatinn of the ligand-binding specificities of the alpha2beta1 and alpha1beta1 integrins in a novel 3-dimensional in vitro model of pancreatic cancer Pancreas. 34:220-8.
73. Gullberg, D., Velling, T., Sjoberg, G. et al. 1995. Up-regulation of a novel integrin alpha-chain (alpha mt) on human fetal myotubes. Dev. Dyn., 204:57-65.
74. Guo, W. and Giancotti, F.G. 2004. Integrin signalling during himor progression. Nat. Rev. Mol. Cell. Biol., 5:816-26.
75. Guo, H.B., Lee, I., Bryan, B.T. et al. 2005. Deletion of mouse embryo fibroblast N. acetylglucosaminyltransferase V stimulates alpha5beta1 integrin expression mediated by the protein kinase C signaling pathway. J. Biol. Chem., 280:8332-42.
76. Guo, W., Pytayeva, Y., Pepe, A. et al. 2006. β4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell., 126:489-502.
77. Gutheil, J.C., Campbell, T.N., Pierce, P.R. et al. 2000. Targeted antiangiogenic therapy for cancer using vitaxin: A humanized monoclonal antibody to the integrin αVβ3. Clinical Cancer Research, 6:3056-61.
78. Haier, J., Goldmann, U., Hotz, B. et al. 2002. Inhibition of tumor progression and neoangiogenesis using cyclic RGD-peptides in a chemically induced colon carcinoma in rats. Clin. Exp. Metastasis, 19:665-72.
79. Hallahan, D.E., Qu, S., Geng, L. et al. 2001. Radiation-mediated control of drug delivery. Am. J Clin. Oncol., 24:473-80.
80. Harms, J.F., Welch, D.R., Samant, R.S. et al. 2004. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin. Exp. Metastasis, 21:119-28.
81. Haubner, R., Kuhnast, B., Mang, C. et al. 2004. [18F]Galacto-RGD: synthesis, radiolabelling, metabolic stability and radiation dose estimates. Bioconjug. Chem., 15:61-9.
82. Haubner, R., Wester, q.J., Weber, W.A. et al. 2001. Noninvasive imaging of vβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res., 61:1781-5.
83. Hedin, U., Roy, J. and Tran, P.K. 2004. Control of smooth muscle cell proliferation in vascular disease. Curr. Opin. Lipidol., 15:559-65.
84. Heino, J. 2000. The collagen receptor integrins have distinct ligand recognition and signaling functions. Matrix Biol., 19:319-23.
85. Herold-Mende, C., Kartenbeck, J., Tomakidi, P. et al. 2001. Metastatic growth of squamous cell carcinomas is correlated with upregulation and redistribution of hemidesmosomal components. Cell. Tissue. Res., 306:399-408.
86. Hirsdh, E., Iglesias, A., Potocnik, A.J. et al. 1996. Impaired migration but not differentiation of haematopoietic stem cells in the absence of beta1 intpgrins. Nature, 380:171-5.
87. Hollenbeck, S., Itoli, H., Louie, O. et al. 2004. Type I collagen synergistically enhances PDGF-induced smooth muscle cell proliferation through pp60src-dependent crosstalk between the alpha2beta1 integrin and PDGF beta receptor. Biochem. Biophys. Res. Commun., 325:328-37.
88. Huang, X., Wu, J., Zhu, W. et al. 1998. Expression of the human integrin beta6 subunit in alveolar type II cells and bronchiolar epithelial cells reverses lung inflammation in beta6 knockout mice. Am. J. Respir. Cell. Mol, Biol., 19:636-42.
89. Humphries, M.J. 2000. Integrin structure. Biochem. Soc. Trans., 28:311-39.
90. Hsia, D.A., Lim, S.T., Bernard-Trifilo, J.A. et al. 2005. Integrin alpha4beta1 promotes focal adhesion kinase-independent cell motility via alpha4 cytoplasmic domain-specific activation of c-Src. Mol. Cell. Biol., 25:9700-12.
91. Hynes, R.O. 2002. Integrins: bidirectional, allosteric signaling machines. Cell., 110:673-87.
92. Ishii, Y., Ochiai, A., Yamada, T. et al. 2000. Integrin alpha6beta4 as a suppressor and a predictive marker for peritoneal dissemination in human gastric cancer. Gastroenterology, 118:497-506.
93. Jackson, T., Clark, S., Berryman, S. et al. 2004. Integrin {alpha}v {beta}8 Functions as a Receptor for Foot-and-Mouth Disease Virus: Role of the {beta}-Chain Cytodomain in Integrin-Mediated Infection. J. Virol., 78:4533-40.
94. Jackson, T., Mould, A.P., Sheppard, D. et al. 2002. Integrin alpha v beta1 is a receptor for foot-and-mouth disease virus. J. Virol., 76:935-41.
95. Jackson, T., Sharma, A., Ghazaleh, R.A. et al. 1997. Arginineglycine-aspartic acid-specific binding by foot-and4mouth disease viruses to the purified integrin alpha v beta 3 in vitro. J. Virol., 71:8357-61.
96. Jackson, T., Sheppard, D., Denyer, , M., Blakemore, W. and King, A.M. 2000. The epithelial integrin alpha v beta 6 is a receptor for foot-and-mouth disease virus. J. Virol., 74:4949-56.
97. Jan, Y., Matter, M., Pai, J.T. et al. 2004. A mitochondrial protein, Bit1, mediates apoptosis regulated by integrins and Groucho/TLE corepressors. Cell., 116:751-62.
98. Jo, M., Thomas, K.S., Wu, L, et al. 2003. Soluble urokinase-type plasminogen activator receptor inhibits caocer cell growth and invasion by direct urokinase-independent effects on cell signaling. J. Biol. Chem., 278:46692-8.
99. Jodele, S., Chantrain, C.F., Blavier, L. et al. 2005. The contribution of bone marrow-derived cells to the tumor varculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res., 65:3200-8.
100. Jones, J., Watt, F.M. and Speight, P.M. 1997. Changes in the expression of alpha v integrins in oral squamous cell carcinomas. J. Oral Pathol. Med., 26:63-8.
101. Joshi, P., Chung, C.Y., Aukhil, I. et al. 1993. Endothelial cells adhere to the RGD domain and the fibrinogen-like terminal knob of tenascin. J. Cell. Sci., 106:389-400.
102. Kallio, J.P., Mikkelsson, J., Tammela, T.L. et al. 2006. Genetic variation in platelet integrin alpha IIb beta 3 (GPIIb/IIIa) and the metastatic potential of renal cell carcinoma. BJU Int., 9:201-4.
103. Kang, I.C., Lee, Y.D. and Kim, D.S. 1999. A novel disintegrin salmosin inhibits tumor angiogenesis. Cancer Res., 59:3754-60.
104. Karczewski, J., Knudsen, K.A. and Smith, L. 1989. The interaction of thrombospondin with platelet glycoprotein GPIIb-IIIa. J. Biol. Chem., 264:21322-6.
105. Karadag, A., Ogbureke, K.U., Fedarko, N.S. et al. 2004. Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)bet3 integrin in osteotropic cancer cell invasion. J. Natl. Cancer Inst., 96:956-65.
106. Kennel, S.J., Foote, L.J., Falcioni, R. et al. 1989. Analysis of the tumor-associated antigen TSP-180. Identity with α6β4 in the integrin superfamily. J. Biol. Chem., 264:15515-21.
107. Kerr, J.S., Slee, A.M. and Mousa, S.A. 2002. The alpha V integrin antagonists as novel anticancer agents: an update. Expert Opin. Investig. Drugs, 11:1765-74.
108. Kim, S., Bell, K., Mousa, S.A. et al. 2000. Regulation of angiogenesis in vivo by ligation of integrin α52b1 with the central cell-binding domain of fibronectin. American Journal of Pathology, 156:1345-62.
109. Kimura, N., Toyoshima, T., Kojima, T. et al. 1998. Entactin-2: a new member of basement membrane protein with high homology to entactin/ nidogen. Exp. Cell. Res., 241:36-45.
110. Kippenberger, S., Loitsch, S., Muller, J. et al. 2004. Ligation of the beta4 intigrin triggers adhesion behavior of human keratinocytes by an "inside-out" mechanism. J. Invest. Dermatol., 123:444-51.
111. Kloczewiak, M., Timmons, S. and Bednarek, M.A. 1989. Platelet receptor recognition domain on the gamma chain of human fibrinogen and its synthetic peptide analogues. Biochemistry, 28:2915-9.
112. Kramer, R.H., Vu, M.P., Cheng, Y.F. et al. 1991. Laminin-binding integrin alpha 7 beta 1: functional characterization and expression in normal and malignant melanocytes. Cell. Regul., 2:805-17.
113. Kumar, C.C. 2003. Integrin αvβ3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr. Drug. Targets, 4:123-31.
114. Kumar, C.C., Malkowski, M., Yin, Z. et al. 2001. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3. and alpha(v)beta5 integrin receptor antagonist. Cancer Res., 61:2232-8.
115. Kuwada, S.K., Kuang, J. and Li, X. 2005. Inlegrin alpha5/beta1 expression mediates HER-2 down-Tegulation in colon caneer cells. J. Biol. Chem., 280:19027-35.
116. Lee, J.W. and Juliano, R.L. 2000. Alpha5beta1 integrin protects intestinal epithelial cells from apoptosis through a phosphatidylinositol 3-kinase and protein kinase B-dependent pathway. Mol. Biol. Cell., 11:1973-87.
117. Li, F., Redick, S.D., Erickson, H.P. et al. 2003. Force measurements of the alpha5beta1 integrin-fibronectin interaction. Biophys. J., 84:1252-62.
118. Li, J., Tan, H., Dong, X. et al. 2007. Antisense integrin alphaV and beta3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas. Dig. Liver Dis., 39:557-65.
119. Lipscomb, E.A., Dugan, A.S., Rabinovitz, I. et al. 2003. Use of RNA interference to inhibit integrin (alpha6beta4)-mediated invasion and migration of breast carcinoma cells. Clin. Exp. Metastasis, 20:569-76.
120. Lipscomb, E.A., Simpson, K.J., Lyle, S.R. et al. 2005. The alpha6beta4 integrin maintains the survival of human breast carcinoma cells in vivo. Cancer Res., 65:10970-6.
121. Liu, B., Ordonez-Ercan, D., Fan, Z. et al. 2007. Downregulation of erbB3 abrogates erbR2-mediated tamoxifen resistance in breast cancer cells. Int. J. Cancer, 120:874-82.
122. Lopez-Conejo, M.T., Ohno, N., Tumay, J. et al. 2002. Interaction of fibronectin with human colon adenocarcinoma cells: effect on the in vivo tumorigenic capacity. Oncology, 62:371-80.
123. Lopez, M.A., Mayer, U., Hwang, W. et al. 2005. Force transmission, compliance, and viscoelasticity are altered in the alpha7-integrin-null mouse diaphragm. Am. J. Physiol. Cell. Physiol., 288:C282-9.
124. Maglott, A., Bartik, P., Cosgun, S. et al. 2006. The small alpha5beta1 integrin antagonist, SJ749, reduces proliferation and clonogenicity of human astrocytoma cells. Cancer Res., 66:6002-7.
125. Marinelli, L., Meyer, A., Heckmann, D. et al. 2005. Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists. J. Med. Chem., 48:4204-7.
126. Markland, F.S., Shieh, K., Zhou, Q. et al. 2001. A novel snake venom disintegrin that inhibits human varian cancer dissemination and angiogenesis in an orthotopic nude mouse model. Haemostasis, 31:183-91.
127. Marlin, S.D. and Springer, TA. 1997. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell., 51:813-9.
128. Marcinkiewicz, C., Weinreb, P.H., Calvete, J.J. et al. 2003. Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo. Cancer Res., 63:2020-3.
129. Martin, P.L., Jiao, Q., Cornacoff, J. et al. 2005. Absence of adverse effects, in cynomolgus macaques treated with CNTO 95, a fully human anti-alpha V integrin monoclonal antibody, despite widespread tissue binding. Clin. Cancer Res., 11:6959-65.
130. Maubant S., Saint-Dizier, D, Boutillon, M. et al. 2006. Blockade of alpha V beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood, 108:3035-44.
131. McCabe, N.P., De, S., Vasanji, A. et al. 2007. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene, 26:6238-43.
132. McHugh, K.P., Hodivala-Dilke, K., Zheng, M.H. et al. 2000. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Invest, 105:433-40.
133. McLane, M.A., Sanchez, E.E., Wong, A. et al. 2004. Disintegrins. Curr. Drug Targets Cardiovasc. Haematol. Disord., 4:327-55.
134. McNeel, D.G., Eickhoff, J., Lee, F.T. et al., 2005. Phase I trial of a monoclonal antibody specific for alphaVbeta3 integrin (MEDI-522) in patients with advanced malignapcies, including an assessment of effect-on tumor perfusion. Clin. Cancer Res., 11:7851-60.
135. McQuade, P. and Knight, L.C. 2003. Radiopharmaceuticals for targeting the angiogenesis marker αvβ3. Q. J. Nucl. Med., 47:209-20.
136. McQuade, P., Knight, L.C. and Welch, M.J. 2004. Evaluation of 64Cu-and 1251-radiolabeled bitistatin as potential agents for targeting alphavbeta3 integrins in tumor angiogenesis. Bioconjug Chem., 15:988-96.
137. Meerovitch, K., Bergeron, F., Leblond, L. et al. 2003. A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces apoptosis of angiogenic endothelial cells on type I collagen. Vascul Pharmacol., 40:77-89.
138. Mercurio, A.M., Rabinovitz, I. and Shaw, L.M. 2001. The alpha6 beta 4 integrin and epithelial cell migration. Curr Opin. Cell. Biol., 13:541-5.
139. Minagar, A., Sheremata, W.A., Vollmer, T.L. et al. 2000. Reduction of relapses in multiple sclerosis after anti-alpha4 integrin antibody (natalizumab). International Journal of MS Care, 3:1-6. Available at http://www.mscare.com.
140. Mitjans, F., Meyer, T., Fittschen, C. et al. 2000. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int. J. Cancer, 87:716-23.
141. Mitjans, F., Sander, D., Adan, J. et al. 1995. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J. Cell. Sci., 108:2825-38.
142. Miyata, S., Koshikawa, N., Yasumitsu, H. et al. 2000. Trypsin stimulates integrin alpha(5)beta(1)-dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2. J. Biol. Chem., 275:4592-8.
143. Mousa, S.A. 2002. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Curr. Opin. Chem. Biol., 6:534-41.
144. Mu, D., Cambier, S., Fjellbirketand, L. et al. 2002. The integrin alpha v beta 8 mediates epithelial homeostasis through MT1-MMPdependent activation of TGF-beta1. J. Cell. Biol., 157:493-507.
145. Muchowski, P.J., Zhang, L., Chang, E.R. et al. 1994. Functional interaction between the integrin antagonist neutrophil inhibitory factor and the I domain of CD11b/CV18. J. Biol. Chem., 269:26419-23.
146. Mullamitha, S.A., Ton, N.C., Parker, G.J. et al. 2007. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin. Cancer Res., 13:2128-35.
147. Munger, J.S., Huang, X., Kawakatsu, H. et al. 1999. The integrin alpha v beta 6 binds and activates latent TGF beta, 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell., 96:319-28.
148. Murillo, C.A., Rychahou, P.G. and Evers, B.M. 2004. Inhibition of alpha5 integrin decreases PI3K activation and cell adhesion of human colon cancers. Surgery, 136:143-9.
149. Niewiarowski, S., McLane, M.A., Kloczewiak, M. et al. 1994. Disintegrins and other naturally occurring antagonists of platelet fibrinogen receptors. Semin, Hematol., 31:289-300.
150. O'Connor, P., Goodman, A., Willmer-Hulme, A.J. et al. 2004. Randomized multicentre trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology, 62:2038-43.
151. O'Connor, P., Miller, D., Riester, K. et al. 2005. Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. Multiple Sclerosis, 11:568-72.
152. Paddison, P.J. and Hannon, G.J. 2003. siRNAs and shRNAs: skeleton keys to the human genome. Curr. Opin. Mol. Ther., 5:217-22.
153. Parise, L.V., Lee, J. and Juliano, R.L. 2000. New aspects of integrin signaling in cancer. Semin. Cancer Biol., 10:407-14.
154. Paulhe, F., Racaud-Sultan, C., Ragab, A. et al. 2001. Differential regulation of phosphomositide metabolism by alphaVbeta3 and alphaVbeta5 integrins upon smooth muscle cell migration. J. Biol. Chem., 276:41832-40.
155. Pawar, S.C., Demetriou, M.C., Nagle, R.B. et al. 2007. Integrin alpha6 cleavage: a novel modification to modulate cell migration. Exp. Cell. Res., 313:1080-9.
156. Perlino, E., Lovecchio, M., Vacca, R.A. et al. 2000. Regulation of mRNA and protein levels of beta1 integrin variants in human prostate carcinoma. Am. J. Pathol., 157:1727-34.
157. Popova, S.N., Barczyk, M., Tiger, C.F. et al. 2007. {alpha)11(beta) 1 Integrin-Dependent Regulation of Periodontal Ligament Function in the Erupting Mouse Incisor. Mol. Cell. Biol., 27:4306-16.
158. Pytela, R., Pierschbacher, M.D. and Ruoslahti, E. 1985. A 125/115-kDa cell surface receptor specific for vitronectin interacts with the arginineglycine-aspartic acid adhesion sequence derived from fibronectin. Proc. Natl. Acad. Sci., U.S.A. 82:5766-70.
159. Rahimi, N., Hung, W., Tremblay, E. et al. 1998. c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. J. Biol. Chem., 273:33714-21.
160. Ramakrishnan, V., Bhaskar, V., Law, D.A. et al. 2006. Preclinical evaluation of an anti-alpha5betal integrin antibody as a novel anti-angiogenic agent. J. Exp. Ther. Oncol., 5:273-86.
161. Ramos, D.M., But, M., Regezi, J., et al. 2002. Expression of integrin beta 6 enhances invasive behavior in oral squamous cell carcinoma. Matrix Biol., 21:297-307.
162. Reinmuth, N., Liu, W., Ahmad, S.A. et al. 2003. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res., 63:2079-87.
163. Reynolds, A.R., Reynolds, L.E., Nagel, T.E. et al. 2004. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in β3-integrin-deficient mice. Cancer Research, 64:8643-50.
164. Rhodes, A. 2005. Developing a cell line standard for HER2/neu. Cancer Biomark, 1:229-32.
165. Risau, W. 1997. Mechanisms of angiogenesis. Nature, 386:671-4.
166. Rodier, J.M., Valles, A. and Denoyelle, M. 1995, pp60c-src is a positive regulator of growth factor-induced cell scattering in a rat bladder carcinoma cell line. J. Cell. Biol., 131:761-73.
167. Ruegg, C. and Mariotti, A. 2003. Vascular integrins: Pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cellular and Molecular Life Sciences, 60:1135-57.
168. Ruggeri, Z.M., De Marco, L. and Gatti, L. 1983. Platelets have more than one binding site for von Willebrand factor. J. Clin. Invest 72:1-12.
169. Sabherwal, Y., Rothman, V.L., Dimitrov, S. et al. 2006. Integrin alpha2beta1 mediates the anti-angiogenic and anti-tumor activities of angiocidin, a novel tumor-associated protein. Exp. Cell. Res., 312:2443-53.
170. Sakai, T., Zhang, Q., Fassler, R. et al. 1998. Modulation of beta1A integrin functions by tyrosine residues in the beta1 cytoplasmic domain. J. Cell. Biol., 141:527-38.
171. Scarborough, R.M., Kleiman, N.S. and Phillips, D.R. 1999. Platelet Glycoprotein IIb/IIIa Antagonists: What Are the Relevant Issues Concerning Their Pharmacology and Clinical Use? Circulation, 100:437-44.
172. Schnapp, L.M., Breuss, J.M., Ramos, D.M. et al. 1995. Sequence and tissue distribution of the human integrin alpha 8 subunit a beta 1-associated alpha subunit expressed in smooth muscle cells. J. Cell. Sci., 108:537-44.
173. Shen, X. and Falzon, M. 2006. PTH-related protein upregulates integrin alpha6beta4 expression and activates Akt in breast cancer cells. Exp. Cell. Res., 312:3822-34.
174. Shen, X., Mula, R.V., Evers, B.M. et al. 2007. Increased cell survival, migration, invasion, and Alt expression in PTHrP-overexpressing LoVo colon cancer cell lines. Regul. Pept., 141:61-72.
175. Senger, D.R., Perruzzi, C.A., Streit, M. et al. 2002. The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am. J. Pathol., 160:195-204.
176. Shaw, L.M. 2001. Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphomositide 3-OH kinase and promotion of invasion. Mol. Cell. Biol., 21:5082-93.
177. Sheu, J.R., Wu, C.H., Chen, Y.C. et al. 2001. Mechanisms in the inhibition of neointimal hyperplasia with triflavin in a rat model of ballooh angioplasty. J. Lab. Clin. Med., 137:270-8.
178. Shimaoka, M., and Springer, T.A. 2004. Therapeutic antagonists and the conformational regulation of the beta2 integrins. Curr. Top. Med. Chem., 4:1485-95.
179. Silvestre, J.S., Thery, C., Hamard, G. et al. 2005. Lactadherin promotes VEGF-dependent neovascularization. Nature Medicine, 11:499-506.
180. Song, E., Lee, S.K., Wang, J. et al. 2003. RNA interference targeting Fas protects mice frm fulminant hepatitis. Nature Med., 9:347-51.
181. Stroeken, P.J., van Rijthoven, E.A., Boer, E. et al. 2000. Cytoplasmic domain mutans of beta1 integrin, expressed in beta 1-knockout lymphoma cells, have distinct effects on adhesion, invasion and metastasis. Oncogene, 19:1232-8.
182. Sabherwal, Y., Rothman, V.L., Dimitrov, S. et al. 2006. Integrin alpha2betal mediates the anti-angiogenic and anti-tumor activities of angiocidin, a novel tumor-associated protein. Exp. Cell. Res., 312:2443-53.
183. Sudhakar, A., Nyberg, P., Keshamouni, V.G. et al. 2005. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1 beta1 integrin. J. Clin. Invest., 115:2801-10.
184. Swenson, S., Costa, F., Minea, R. et al. 2004. Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. Mol. Cancer. Therl., 3:499-511.
185. Taga, T., Suzuki, A., Gonzalez-Gomez, I. et al. 2002. Alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int. J. Cancer., 98:690-7.
186. Tanaka, Y., Mimori, K., Shiraishi, T. et al. 2000. Alpha6 integrin expression in esophageal carcinoma. Int. J. Oncol., 16:725-9.
187. Takanami, I. 2005. Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer. BMC Cancer, 5:1-7.
188. Taylor, M.R., Couto, J.R., Scallan, C.D. et al. 1997. Lactadherin (formerly BA46), a membrane-associated glycoprotein expressed in human milk and breast carcinomas, promotes Arg-Gly-Asp (RGD)-dependent cell adhesion. DNA Cell. Biol., 16:861-9.
189. Thomas, G.J., Lewis, M.P., Hart, I.R. et al. 2000. AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int. J. Cancer, 92:641-50.
190. Thomas, G.J., Nystrom, M.L. and Marshall, J.F. 2006. Alphavbeta6 integrin in wound healing and cancer of the oral cavity. J. Oral. Pathol. Med., 35:1-10.
191. Thomas, G.J., Poomsawat, S., Lewis, M.P. et al. 2001. Alphavbeta6 integrin upregulates matrix metalloproteinase 9 and promotes migration of normal oral keratinocytes. J. Invest Dermatol., 116:898-904.
192. Tiger, C.F., Fougerousse, F., Grundstrom, G. et al. 2001. Alpha11beta1 integrin is a receptor for interstitial collagens involved in cell migration and collagen reorganization on mesenchymal nonmuscle cells. Dev. Biol., 237:116-29.
193. Travis, M.A., Humphries, J.D. and Humphries, M.J. 2003. An unraveling tale of how integrins are activated from within. Trends. Pharmacol. Sci., 24:192-7.
194. Trikha, M., Timar, J., Zacharek, A. et al. 2002a. Role for beta3 integrins in human melanoma growth and survival. Int. J. Cancer, 101:156-67.
195. Trikha, M., Zhou, Z., Timar, J. et al. 2002b. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res., 62:2824-33.
196. Trikha, M., Zhou, Z., Nemeth, J.A. et al. 2004. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int. J. Cancer., 110:326-35.
197. Tsuji, T. 2004. Physiological and pathological roles of alpha3beta1 integrin. J. Memb. Biol., 200:115-32.
198. Tsuji, T., Kawada, Y., Kai-Murozono, M. et al. 2002. Regulation of melanoma cell migration and invasion by laminin-5 and alpha3beta1 integrin (VLA-3). Clin. Exp. Metastasis, 19:127-34.
199. Tucker, G.C. 2003. Alpha v integrin inhibitors and cancer therapy. Curr. Opin. Investig Drugs, 4:722-31.
200. Tulla, M., Pentikainen, O.T., Viitasalo, T. et al. 2001. Selective binding of collagen subtypes by integrin alpha 11, alpha 21, and alpha 101 domains. J. Biol. Chem., 276:48206-12.
201. Venter, J.C., Adams, M.D., Myers, E.W, et al. 2001. The sequence of the human genome. Science, 291:1304-51.
202. Weaver, V.M., Lelievre, S., Lakins, J.N. et al. 2002. Beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell., 2:205-16.
203. Wei, Y., Tang, C.H., Kim, Y. et al. 2007. Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells. J. Biol. Chem., 282:3929-39.
204. Weinacker, A., Ferrando, R., Elliott, M. et al. 1995. Distribution of integrins alpha v beta 6 and alpha 9 beta 1 and their known ligands, fibronectin and tenascin, in human airways. Am. J. Respir. Cell. Mol. Biol., 12:547-56.
205. Weinreb, P.H., Simon, K.J., Rayhorn, P. et al. 2004. Function-blocking integrin alphaybeta6 monoclonal antibodies: distinct ligand-mimetic and nonligand- mimetic classes. J. Biol. Chem., 279:17875-87.
206. White, D.E., Kurpios, N.A. Zuo, D. et al. 2004. Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell., 6: 159-70.
207. Wick, W., Naumann, U. and Weller, M. 2006. Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. Curr. Pharm. Des., 12:341-9.
208. Woska, J.R. Jr., Morelock, M.M., Jeanfavre, D.D. et al. 1996. Characterization of molecular interactions between intercellular adhesion molecule-1 and leukocyte function- associated antigen-1. J. Immunol., 156:4680-5.
209. Wright S.D. and Silverstein, S.C. 1983. Receptors for C3b and C3bi promote phagocytosis but not the release of toxic oxygen from human phagocytes. J. Exp. Med., 158:2016-23.
210. Wu, W.B., Peng, H.C. and Huang, T.F. 2003. Disintegrin causes proteolysis of beta-catenin and apoptosis of endothelial cells. Involvement of cell-cell and cell-ECM interactions in regulating cell viability. Exp. Cell. Res., 286:115-27.
211. Xiong, J.P., Stehle, T., Diefenbach, B. et al. 2001. Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science, 294:339-45.
212. Xiong, J.P., Stehle, T., Goodman, S.L.. et al. 2004. A novel adaptation of the integrin PS1 domain revealed from its crystal structure. J. Biol. Chem., 279:40252-4.
213. Xiong, J.P., Stehle, T., Zhang, R. et al. 2002. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science, 296:151-5.
214. Yang, C., Zeisberg, M., Lively, J.C. et al. 2003. Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res., 63:8312-7.
215. Yao, E.S., Zhang, H., Chen, Y.Y. et al. 2007. Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res., 67:659-64.
216. Yeh, C.H., Peng, H.C. and Huang, T.F. 1998. Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alpha V beta 3 antagonist and inducing apoptosis. Blood, 92:3268-76.
217. Zhang, D., Pier, T., McNeel, D.G., Wilding, G. et al. 2007. Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels-a pharmacodynamic study. Invest. New Drugs, 25:49-55.
218. Zhang, L. and Plow, E.F. 1996. A discrete site modulates activation of I domains. Application to integrin alphaMbeta2. J. Biol. Chem., 271:29953-7.
219. Zheng, D.Q., Woodard, A.S., Fornaro, M. et al. 1999. Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res., 59:1655-64.
220. Zheng, D.Q., Woodard, A.S., Tallini, G. et al. 2000. Substrate specificity of alpha(v)beta(3) integrin-mediated cell migration and phosphatidylinositol-3-kinase/AKT pathway activation. J. Biol. Chem., 275:24565-74.
221. Zhou, X., Murphy, F.R., Gehdu, N. et al. 2004. Engagement of alphavbeta3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J. Biol. Chem., 279:23996-4006.
222. Zhou, Q., Nakada, M.T., Arnold, C. et al. 1999, Contortrostatin, a dimeric disintegrin from Agkistrodon contortril contortrix, inhibits angiogenesis. Angiogenesis, 3:259-69.
223. Ziober, B.L., Chen, Y.Q., Ramos, D.M. et al. 1999. Expression of the alpha7beta1 laminin receptor suppresses melanoma growth and metastatic potential. Cell. Growth Differ., 10:479-90.
224. Zutter, M.M., Santoro, S.A., Staatz, W.D. et al. 1995. Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc. Natl. Acad. Sci., U.S.A. 92:7411-5.